Pediatricians Should Know About Kratom: A Pediatrician’s Perspective

AUTHORS

Opinion  Article

Whitney Eldridge

St. Joseph Women’s Hospital, Florida, USA

Introduction

In the current opioid epidemic, opioid use among pregnant women and the incidence of neonatal abstinence syndrome (NAS) is on the rise [1, 2]. NAS is a constellation of withdrawal symptoms in newborns secondary to chronic in utero exposure. It is most frequently attributed to maternal prescription and illicit opioid use [3]. Compounding the stress that can come with pregnancy, mothers with opioid addiction also face guilt over opioid’s effects on their unborn babies, obstacles to finding obstetrical providers comfortable with caring for opioid-dependent mothers, and fear over social services involvement [4]. It is understandable that pregnant women with opioid addiction would look to over-the-counter non-opioid alternatives advertised as safe and effective for treatment of opioid withdrawal. Indeed, non-opioid treatments of opioid addiction would seem to offer benefits for both mother and baby. In the current opioid crisis, search for such alternatives has intensified. Kratom, an herbal supplement, is heavily advertised as a natural, non-opioid aid for opioid withdrawal and is increasingly used by those with histories of opioid dependency [5,6,7]. It is likely that pediatricians will increasingly encounter kratom exposure in newborns and pediatric patients.

 

Kratom is indigenous to Southeast Asia and has long been used there recreationally and medicinally to treat opium addiction [8, 9]. It is an indole alkaloid and its main components, mitragynine and 7-hydroxymitragynine, act as agonists at opioid receptors. Mitragynine is less potent than morphine, while 7-hydroxymitragynine is more potent. Their binding to opioid receptors induces an opioid-like analgesia and euphoria but seemingly without respiratory depression and other noxious symptoms attributed to morphine. Kratom also interacts with non-opioid receptors (α-2 adrenergic, serotonin and dopamine receptors) which may be associated with its perceived lack of respiratory depression [9, 20].

 

Chronic users of kratom can develop dependency. Abstinence results in withdrawal symptoms similar to that of opioid withdrawal: rhinorrhea, insomnia, lacrimation, myalgias, arthralgias, myoclonus, depression, anxiety, and increased pain severity [8, 13, 21-23]. Symptoms of kratom toxicity seen in adults include: palpitations, chest pain, tachycardia, hypertension, diaphoresis, altered mental status, agitation, central nervous system depression, seizures, diarrhea, abdominal pain and hepatotoxicity [22, 23]. Withdrawal has been managed with clonidine and opioids and toxicity with benzodiazepines [22, 23].

Kratom use in the United States is on the rise and is increasingly used by those with opioid dependency to treat opioid withdrawal. It is available for purchase online and in stores as a tea, powder or capsules. Online users testify to its alleviation of opioid withdrawal and its addictive potential [5-7, 24]. Its classification as an opioid is debated. Advocates argue its alleviation of opioid withdrawal without respiratory depression make it a potential therapeutic for opioid dependency and regulating it would potentially harm those who use kratom to successfully overcome opioid addiction [25-27]. Without regulation products marketed as kratom have the potential to be adulterated to achieve a higher potency and mixed with dangerous contaminants such as a recently linked Salmonella outbreak [28-30]. Kratom is illegal in several states and the US Drug Enforcement Administration has considered scheduling kratom. In February 2018 the US Food and Drug Administration released a statement classifying kratom as an opioid based on review of the scientific literature and computational modeling of its receptor binding [31]. Policing kratom may stifle efforts to research its potential therapeutic benefits and adverse effects. [32] Currently, kratom is unregulated and widely available for purchase.

Kratom’s effects on pregnant women and the fetus and newborn are largely unknown. Few cases are reported in the literature but seem to be increasing among pregnant women with a history of chronic opioid use. Women experience withdrawal when discontinuing kratom and their newborns can develop NAS requiring pharmacologic treatment, prolonging hospital stay and potentially resulting in separation of mom and baby. Symptoms seen in newborns are typical of NAS due to opioids (diarrhea, tachypnea, excessive cry, excoriations, poor feeding) and seem to present 1—2 days after birth [22, 23, 33-37]. The American Kratom Society (https://www.americankatom.org/science) does not recommend use of kratom by pregnant or breastfeeding women. Transmission through breastmilk is unstudied, but one case reports improvement in withdrawal symptoms with breastfeeding [35]. Most of the published cases of kratom use by pregnant women do not report amounts consumed, however duration and frequency are cited as chronic and daily [22,23,33-37].

Kratom cannot be detected on standard urine drug screens but qualitative immunologic assays are in development [38, 39]. Detection in urine is by liquid chromatography or mass spectrometry. Time to results is highly variable but can take 1-2 weeks, well after signs of withdrawal present [33]. Pediatricians and obstetricians must rely on history-taking to suspect kratom exposure and should enquire about kratom use from all women with a history of opioid dependency. Some recommend screening for kratom in all pregnant women with a history of opioid use by sending urine for specialized testing [33].

Pediatricians, obstetricians and those caring for pregnant women and newborns with potential substance exposure need to be aware of kratom and its potential for dependency and withdrawal. Further research is needed to guide management of kratom-exposed newborns and pregnant women. Providers caring for pregnant women should counsel mothers on the risk of using kratom for their health and their babies’ just as they would any other legal substance with the potential to negatively impact pregnancy.

References

1.Ailes EC, Dawson AL, Lind JN, Gilboa SM, Frey M, et al; (2012) Centers for Disease Control and Prevention (CDC). Opioid prescription claims among women of reproductive age-United States,. MMWR Morb Mortal Wkly Rep. 2015; 64(2):37-41.

2.Ko JY, Patrick SW, Tong VT, Patel R, Lind JN, Barfield WD. Incidence of neonatal abstinence syndrome — 28 states, 1999–2013. MMWR Morb Mortal Wkly Rep. 2016; 65:799–802. doi: 10.15585/mmwr.mm6531a2

3.Kocherlakota P. Neonatal abstinence syndrome, Pediatrics. 2014; 134(2): e547-e561. doi:10.154/peds.2013-3524.

4.Mattocks KM, Clark R, Weinreb L. (2017) Initiation and Engagement with Methadone Treatment among Pregnant and Postpartum Women. Women’s Health Issues.; 27(6): 646-651.

5.Boyer EW, Babu KM, Macalino GE, Compton W. ( 2007) Self-treatment of opioid withdrawal with a dietary supplement, Kratom. Am J Addict. 2007;16:352-356.

6.Smith KE, Lawson T. (2017)Prevalence and motivations for Kratom use in a sample of substance users enrolled in a residential treatment program. Drug and Alcohol Dependence. 180:340-348.

7.Singh D, Narayanan S, Vicknasingam B, Corazza O, Santacroce R,( 2017) et al. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia. Hum Psychopharmacol. 2017 May;32(3).

8.Suwanlert S. A (1975) Study of Kratom eaters in Thailand. Bulletin on Narcotics. 27(3): 21-27.

9.Grewal K. (1932) Observations on the pharmacology of Mitragynine. J Pharmacol Exp Ther. 1932;46:251-271.

10.Watanabe K, Yano S, Horie S, Yamamoto LT. (1997) Inhibitory effect of Mitragynine, an alkaloid with analgesic effect from Thai medicinal plant Mitragyna speciosa, on electrically stimulated contraction of isolated guinea-pig ileum through the opioid receptor. Life Sci.; 60(12):993-942

11.Thongpradichote S, Matsumoto K, Tohda M, Takayama H, Aimi N, et al. (1998) Dentification of opioid receptor subtypes in antinociceptive actions of supraspinally-administered Mitragynine in mice. Life Sci. 1998;62(16):1371-1378.

12.Varadi A, Marrone GF, Palmer TC, Narayan A, Szabό MR,  et al. (2016) Mitragynine/Corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit β-arrestin-2. J. Med. Chem. ;59:8381-8397. 13.

13.Macko E, Weisbach JA, Douglas B.(1972 )  Some observations on the pharmacology of Mitragynine. Arch Int Pharmacodyn Ther.198:145-161.

14.Kruegel, A.C., and Grundmann, O. (2017) The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology

15Takayama H.(2004) Chemistry and Pharmacology of Analgesic Indole Alkaloids from the Rubiaceous Plant, Mitragyna speciose. Chem. Pharm. Bull. 52(8) 916—928.

16.Matsumoto K, Mizowaki M, Suchitra T, Takayama H, Sakai S, et al. (1996) Antinociceptive action of mitragynine in mice: evidence for the involvement of supraspinal opioid receptors. Life Sci. 1996;59(14):1149-1155.

17. Matsumoto K, Horie S, Ishikawa H, Takayama H, Aimi N, et al. (2004) Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sci. Mar 12;74(17):2143-2155.

18.Takayama H, Ishikawa H, Kurihara M, Kitajima M, Aimi N, et al.(2002) Studies on the Synthesis and Opioid Agonistic Activities of Mitragynine-Related Indole Alkaloids: Discovery of Opioid Agonists Structurally Different from Other Opioid Ligands. J. Med. Chem. 45, 1949-1956.

19.Matsumoto K, Horie S, Takayama H, Ishikawa H, Aimi N, et al. (2005) Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa. Life Sci. Nov 19;78(1):2-7.

20.Matsumoto K, Hatori Y, Murayama T, Tashima K, Wongseripipatana S, et al. (2006) Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa. Nov 7;549(1-3):63-70

21.Singh D, Müller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) ( 2014) Dependence, withdrawal symptoms and craving in regular users. Drug and Alcohol Dependence.:139:132-137.

21.Trakulsrichai S, Tongpo A, Sriapha C, Wongvisawarkorn S, Rittilert P, et al. ( 2013)Kratom abuse in Ramathibodi Poison Center, Thailand: A five-year experience. J Psychoactive Drugs.;45(5):404-408.

22.Cumpston KL, Wills BK, Carter M. (2018) Clinical outcomes after Kratom exposures: A poison center case series. Am J of Emerg Med.;36:134-168.

23.Cinosi E, Martinotti G, Simonoto P, Singh D, Demetrovics Z, et al. (2015) Following “the roots” of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries. BioMed Res. Int

24.Grundmann O, Brown PN, Henninfield J, Swogger M, Walsh Z. (2018) The Therapeutic Potential of Kratom. Addiction .113: 1951-1954.

25.Henningfield JE, Fant RV, Wang DW. (2017)The abuse potential of Kratom according the 8 factors of the controlled substances act: implications for regulation and research. Psychopharmacology.

26.Gauvin D, Zimmerman Z. ( 2018) A reply to Henningfield, Fant & Wang (2018): regulatory action to control kratom is long overdue. Psychopharmacology.

27.Lydecker AG, Sharma A, McCurdy CR, Avery BA, Babu KM, et al (2016) Suspected adulteration of commercial kratom products with 7-hydroxymitragynine. J Med Toxicol.;12(4): 341-349.

28.Kronstrand R, Roman M, Thelander G, Eriksson A. (2011) Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J Anal Toxicol. 2; 35: 242-247.

28.Voelker, R. Kratom Investigation Concludes. JAMA. 2018; 320(5): 431.

29.US Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s scientific evidence on the presence of opioid compounds in Kratom, underscoring its potential for abuse. 2018

30.Prozialeck, W.( 2016) Update on the Pharmacology and Legal Status of Kratom. J Am Osteopath Assoc.; 116(12): 802-809.

31.Smid MC, Charles JE, Gordon AJ, Wright TE.( 2018)  Use of Kratom, an opioid-like traditional herb, in pregnancy. Obstetrics & Gynecology.; 132(4): 926-928.

32.Murthy P, Clark D. An unusual cause for neonatal abstinence syndrome. Pediatrics & Child Health. 2018, pxy084.

33.Mackay L, Abrahams R. (2018) Novel Case of maternal and neonatal kratom dependence and withdrawal. Canadian Family Physician. 64: 121-122.

34.Davidson L, Rawat M, Stojanovski S, Chandrasekharan P.( 2018)  Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to kratom. J Neonatal Perinatal Med..

35.Eldridge WB, Foster C, Wyble L.(2018)  Neonatal Abstinence Syndrome Due to Maternal Kratom Use. Pediatrics. 142(6). E20181839.

36.Limsuwanchote S, Putalan W, Tanaka H, Morimoto S, Keawpradub N, et al. (2018) Development of an immunochromatographic strip incorporating anti-mitragynine monocolonal antibody conjugated to colloidal gold for kratom alkaloids detection. Drug Test Anal. ; 10:1168-1175..

37Smith L, Lin L, Hwang C, Zhou B, Kubitz D, et al. ( 2018 ) Lateral Flow Assessment and Unanticipated Toxicity of Kratom. Chem Res Toxicol.